News | June 17, 2019
Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a...
News | June 12, 2019
Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli...
News | May 23, 2019
The FDA has approved Mayne Pharma Group Limited's Sorilux (calcipotriene) Foam, 0.005% in adolescents 12 years and older. The FDA approved Sorilux in 2010 based on evidence from two eight-week placebo controlled clinical trials in...
Years ago, if someone had told me, as a professional comedian and humorist, that I would author an article in Practical Dermatology®, I would have made a strong wager against it. Back then, I was far too immature to be trusted with...
News | April 25, 2019
The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical...
DermWireTV: AbbVie to Acquire Allergan, Duobrii Launches, SDPA at 25
Sponsored by Ortho Dermatologics
Tazarotene is almost a forgotten entity in management of psoriasis, despite quality data showing it can be both tolerable and effective—when used appropriately.
Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCD
The newest IL-23 blocker for psoriasis may prove to be a blockbuster, according to analysts.
Jerry Bagel, MD, FAAD
The latest research offers insights on the benefits and utility of topical treatment.
Leon Kircik, MD, FAAD